Almirall and the Spanish Society of Pharmacology confer the Pharmacology Award 2008

·The prize promotes research in pharmacology and was awarded during the Annual Spanish Society of Pharmacology Congress held in Bilbao

·The award, of €9,000, has been given to Dr. Francisco Ciruela Alférez for the project “Olygomerization of G-protein coupled receptors in basal ganglia and its relation to Parkinson’s disease”

 

Barcelona, 19 September 2008.- Today, the Award in Pharmacology 2008 was given out during the 30th Congress of the Spanish Society of Pharmacology held in Bilbao from 17 to 19 September. Jointly sponsored by Almirall and the Spanish Society of Pharmacology (SEF), this award is the only one to recognise the quality of a research project to be developed in the Pharmacology field in Spain rather than an already completed work.

This year the award, which includes a prize of €9.000, was given to Dr. Francisco Ciruela Alférez, from the Pharmacology Unit, Faculty of Medicine, University of Barcelona, for the project: “Olygomerization of G-protein coupled receptors in basal ganglia and its relation to Parkinson’s disease”. The results of the project, which is to be carried out during 2008-2009, will be presented at the next Spanish Society of Pharmacology Congress in 2009.

The jury, made up of Dr. Francisco Zaragozá, President of the SEF, and doctors Jesús Llenas and Amadeu Gavaldà, both from Almirall, assessed work through an independent scoring process and subsequent agreement. Dr. Llenas indicates: “This is the seventh year of this award, for which numerous initiatives in different therapeutic areas are presented each time. In selecting the winning project we considered its contribution to the pharmacological arena nowadays, its originality, its structure and the novel potential of its results. Dr. Ciruela’s project, which is focused on Parkinson’s, a disease that affects four million people around the world, covered all these conditions”.

About Almirall

Almirall, an international pharmaceutical company based on innovation and committed to health, headquartered in Barcelona, Spain, researches, develops, manufactures and commercialises its own R&D and licensed drugs with the aim of improving people’s health and wellbeing.

The therapeutic areas on which Almirall focuses its research resources are related to the treatment of asthma, COPD (Chronic Obstructive Pulmonary Disease), rheumatoid arthritis, multiple sclerosis, psoriasis and dermatology in general.

Almirall is currently present in over 70 countries with direct presence in Europe and Latin America through 11 affiliates.

 

 

 

More information:

Ketchum/SEIS

Sonia San Segundo/Patricia Mansilla

sonia.sansegundo@ketchum.com

Tel.: 91 788 32 00